HOME >> BIOLOGY >> NEWS
Cancer-Risk Analysis Program Goes Public

DALLAS - April 27, 1999 - A UT Southwestern Medical Center at Dallas physician-scientist is offering his interactive, comprehensive computer program for breast-cancer risk assessment at no charge to health professionals providing breast care.

Dr. David Euhus, assistant professor of surgical oncology, designed the user-friendly personal computer-based program called "CancerGene," which will collect a family history, draw a pedigree and display probabilities of developing breast cancer at various ages as well as probabilities of inheriting an abnormal breast-cancer-susceptibility gene. Euhus co-directs the Mary L. Brown Breast Cancer Genetics and Risk Assessment Program in the Southwestern Center for Breast Care and is the George and Carol Poston Professor in Breast Cancer Research.

Asked why there is no charge for the computer program, he said, "We're giving it away because it is useful for assisting women who are concerned about their breast-cancer risk. Does there need to be a better reason?"

The program leads breast-care providers through a structured on-screen interview that collects a detailed family history and then displays probabilities in graphs and tables. The outputs include: age-specific probability of developing breast cancer, age-specific probability of developing ovarian cancer and probability of having a BRCA1 or BRCA2 gene mutation. The program employs several models, including Duke University Institute of Statistics and Decisions Sciences' BRCAPRO.

The user also is able to see if the program can suggest another cancer syndrome applicable to the family history by simply clicking on the appropriate button. In addition, "CancerGene" has an easily accessible glossary of cancer syndromes.


'"/>

Contact: Heather Stieglitz
heather.stieglitz@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
27-Apr-1999


Page: 1

Related biology news :

1. Analysis fingers causes of desertification
2. Analysis of gene expression in lymphoid cells can determine lymphoma cancer
3. Analysis of biological clock may lead to greater understanding of human disease
4. Analysis uncovers critical stretches of human genome
5. Newer methods added, scope expanded in new Methods of Soil Analysis Book
6. MelTec GmbH announces new technology for High-Throughput Topological Analysis of human cells
7. Analysis of impact studies reveals how bottom fishing affects seafloor denizens
8. Analysis of flight performance in wandering albatrosses yields insights into foraging patterns of different ages and sexes
9. Analysis of Martian meteorite using unique magnetic microscope
10. Urine Tests Will Do Better Than Pelvic Exams To Save Teens From Serious Effects Of Sexually Transmitted Diseases, UCSF Analysis Shows
11. Farmers Can Afford To Clean Up Gulf Of Mexico, Analysis Shows

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer Risk Analysis Program Goes Public

(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... PMG Research, Benchmark Research, and ... formation of VaxCorps, a network of highly experienced, ... conduct of vaccine trials in healthy adult, elderly, ... successfully conducted over 500 phase I-III vaccine clinical ... influenza as well as a vast array of ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: